ALEC-04 is under clinical development by Alentis Therapeutics and currently in Phase II for Recurrent Head And Neck Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Recurrent Head And Neck Squamous Cell Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ALEC-04’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALEC-04 overview
Alentis Therapeutics overview
Alentis Therapeutics is a clinical-stage biotech company. It develops first-in-class anti-Claudin-1 (CLDN1) antibodies for treating positive tumors and organ fibrosis. The company’s oncology and ADCs (Antibody-Drug Conjugates) pipeline products include ALE.C04 an investigational first-in-class monoclonal antibody designed to treat cancer by targeting exposed Claudin-1 on solid tumors and ALE.P02 and ALE.P03 ADC for the treatment of Claudin-1 Positive Tumors. Alentis Therapeutics’ other pipeline includes Lixudebart for treating ANCA-associated vasculitis, advanced liver fibrosis and idiopathic pulmonary fibrosis. It also investigates next-gen CLDN1 modalities. Alentis Therapeutics is headquartered in Allschwil, Switzerland.
For a complete picture of ALEC-04’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
